PerkinElmer, Inc., a global leader committed to innovating for a healthier world, has announced the launch of the new EUROIMMUN Aspergillus Antigen ELISA.* The enzyme-linked immunosorbent assay is specifically designed to detect the Aspergillus antigen galactomannoprotein and assist in distinguishing invasive aspergillosis (IA).

IA, the most life-threatening form of aspergillus infection, commonly affects the lungs of immunocompromised patients, but pathogens often spread throughout the body to the central nervous system, eyes, heart and kidneys. Cases of IA have a high mortality rate, ranging up to 90%, especially if the central nervous system is impacted.

“Timely detection and diagnosis of this dangerous infection is critical to ensuring proper treatment and preventing fatalities,” said Dr. Wolfgang Schlumberger, Ph.D., CEO of EUROIMMUN, a PerkinElmer company. “Clinical studies have shown that the EUROIMMUN Aspergillus Antigen ELISA delivers high sensitivity and specificity in detecting galactomannoprotein. And, when processed using the automated EUROIMMUN Analyzer system, our ELISA seamlessly integrates into a laboratory workflow for faster detection of Aspergillus infections at an earlier stage.”

Detection of Aspergillus antigen is included in the guidelines of the Infectious Diseases Society of America (IDSA), the European Organization for Research and Treatment of Cancer (EORTC) and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (MSG) as a criterion of a “probable” IA infection.

EUROIMMUN is widely recognized as a global leader in autoimmune testing and an emerging force in infectious disease, allergy and molecular genetic testing. Its expertise and capabilities extend across immunology, cell biology, histology, biochemistry and molecular biology.